Effect of Early Correction of Anemia on the Progression of CKD

American Journal of Kidney Diseases

Volumn 47, Issue 5, 2006, Pages 738-750

  Rossert, Jérôme ^{a,b,c,d,e,f,g}   Levin, Adeera ^{a,b,c,d,e,f,g}   Roger, Simon D ^{a,b,c,d,e,f,g}   Hörl, Walter H ^{a,b,c,d,e,f,g}   Fouqueray, Bruno ^{a,b,c,d,e,f,g}   Gassmann Mayer, Cristiana ^{a,b,c,d,e,f,g}   Frei, Dieter ^{a,b,c,d,e,f,g}   McClellan, William M ^{a,b,c,d,e,f,g}  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ST PAUL S HOSPITAL   (Canada)

^c GOSFORD HOSPITAL   (Australia)

^d UNIVERSITY OF VIENNA   (Austria)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^f Ortho Biotech Europe   (Switzerland)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anemia; chronic kidney disease (CKD); epoetin alfa; erythropoietin

Indexed keywords

IOHEXOL; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ANGINA PECTORIS; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DEATH; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; ENDOCARDITIS; FEMALE; GLOMERULUS FILTRATION RATE; HEART ARREST; HEART INFARCTION; HEART PALPITATION; HEART VENTRICLE TACHYCARDIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INTERMITTENT CLAUDICATION; KIDNEY CANCER; KIDNEY DISEASE; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; NUTRITION; PERIPHERAL ISCHEMIA; PROTEINURIA; PRURITUS; PURE RED CELL ANEMIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SAFETY; THROMBOCYTOPENIA; THROMBOPHLEBITIS; THROMBOSIS; TREATMENT DURATION; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; ANEMIA; CHRONIC DISEASE; DISEASE PROGRESSION; EPOETIN ALFA; FEMALE; GLOMERULAR FILTRATION RATE; HEMATINICS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 33646477844     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.02.170     Document Type: Article

References (47)

1. Coresh J., Astor B.C., Greene T., Eknoyan G., and Levey A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population. Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41 (2003) 1-12
2. Chadban S.J., Briganti E.M., Kerr P.G., et al. Prevalence of kidney damage in Australian adults. The AusDiab kidney study. J Am Soc Nephrol 14 suppl 2 (2003) S131-S138
3. ERA-EDTA Registry. ERA-EDTA Registry 2002 Annual Report (2004), Academic Medical Centre, Amsterdam, The Netherlands. http://www.era-edta-reg.org/files/annualreports/pdf/AnnRep2002.pdf May Available at: www.era-edta-reg.org/files/annualreports/pdf/AnnRep2002.pdf. Accessed January 13, 2004
4. Astor B.C., Muntner P., Levin A., Eustace J.A., and Coresh J. Association of kidney function with anemia. The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 162 (2002) 1401-1408
5. Hsu C.Y., McCulloch C.E., and Curhan G.C. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States. Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13 (2002) 504-510
6. McClellan W., Aronoff S.L., Bolton W.K., et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 20 (2004) 1501-1510
7. Walters B.A., Hays R.D., Spritzer K.L., Fridman M., and Carter W.B. Health-related quality of life, depressive symptoms, anemia, and malnutrition at hemodialysis initiation. Am J Kidney Dis 40 (2002) 1185-1194
8. Abbott K.C., and Bakris G.L. Cardiology patient page. Kidney failure and cardiovascular disease. Cardiology 108 (2003) e114-e115
9. Manjunath G., Tighiouart H., Ibrahim H., et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 41 (2003) 47-55
10. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
11. Locatelli F., Aljama P., Barany P., et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19 suppl 2 (2004) Sii1-Sii47
12. Jones M., Ibels L., Schenkel B., and Zagari M. Impact of epoetin alfa on clinical end points in patients with chronic renal failure. A meta-analysis. Kidney Int 65 (2004) 757-767
13. Rossert J., McClellan W.M., Roger S.D., and Verbeelen D.L. Epoetin treatment. What are the arguments to expect a beneficial effect on renal disease progression?. Nephrol Dial Transplant 17 (2002) 359-362
14. Rossert J., Fouqueray B., and Boffa J.J. Anemia management and the delay of chronic renal failure progression. J Am Soc Nephrol 14 suppl 2 (2003) S173-S177
15. Roth D., Smith R.D., Schulman G., et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 24 (1994) 777-784
16. Kuriyama S., Tomonari H., Yoshida H., Hashimoto T., Kawaguchi Y., and Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77 (1997) 176-185
17. Gouva C., Nikolopoulos P., Ioannidis J.P., and Siamopoulos K.C. Treating anemia early in renal failure patients slows the decline of renal function. A randomized controlled trial. Kidney Int 66 (2004) 753-760
18. Kleinman K.S., Schweitzer S.U., Perdue S.T., Bleifer K.H., and Abels R.I. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function. A double-blind, placebo-controlled trial. Am J Kidney Dis 14 (1989) 486-495
19. Abraham P.A., Opsahl J.A., Rachael K.M., Asinger R., and Halstenson C.E. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients. Am J Nephrol 10 (1990) 128-136
20. Jungers P., Choukroun G., Oualim Z., Robino C., Nguyen A.T., and Man N.K. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 16 (2001) 307-312
21. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
22. Henke M., Laszig R., Rübe C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy. Randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
23. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4 (2003) 459-460
24. Bern J.S. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?. Semin Dial 18 (2005) 22-29
25. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
26. Gaspari F., Perico N., Ruggenenti P., et al. Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 6 (1995) 257-263
27. Bröchner-Mortensen J. A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 30 (1972) 271-274
28. Steiber A.L., Kalantar-Zadeh K., Secker D., McCarthy M., Sehgal A., and McCann L. Subjective Global Assessment in chronic kidney disease. A review. J Ren Nutr 14 (2004) 191-200
29. Combe C., McCullough K.P., Asano Y., Ginsberg N., Maroni B.J., and Pifer T.B. Kidney Disease Outcomes Quality Initiative (K/DOQI) and the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nutrition guidelines, indicators, and practices. Am J Kidney Dis 44 suppl 3 (2004) S39-S46
30. Brorsson B., and Asberg K.H. Katz Index of Independence in ADL. Reliability and validity in short-term care. Scand J Rehabil Med 16 (1984) 125-132
31. Kamper A.L., Strandgaard S., and Leyssac P.P. Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens 5 (1992) 423-430
32. Hannedouche T., Landais P., Goldfarb B., et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 309 (1994) 833-837
33. Klahr S., Schreiner G., and Ichikawa I. The progression of renal disease. N Engl J Med 318 (1988) 1657-1666
34. Ruggenenti P., Perna A., Gherardi G., et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354 (1999) 359-364
35. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
36. Parfrey P.S., Foley R.N., Wittreich B.H., Sullivan D.J., Zagari M.J., and Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16 (2005) 2180-2189
37. Foley R.N., Parfrey P.S., Morgan J., et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58 (2000) 1325-1335
38. Furuland H., Linde T., Ahlmen J., Christensson A., Strombom U., and Danielson B.G. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18 (2003) 353-361
39. McMahon L.P., Mason K., Skinner S.L., Burge C.M., Grigg L.E., and Becker G.J. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 15 (2000) 1425-1430
40. Singh A.K., Bhaduri S., Tang K.L., Klausner M., Corwin M., and Reddan D. Factors associated with hemoglobin (Hb) response in patients (PTS) with anemia of chronic kidney disease (CKD). J Am Soc Nephrol 14 (2003) 457A (abstr)
41. Roger S.D., McMahon L.P., Clarkson A., et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4). Results of a randomized clinical trial. J Am Soc Nephrol 15 (2004) 148-156
42. Keane W.F., Brenner B.M., de Zeeuw D., et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy. The RENAAL Study. Kidney Int 63 (2003) 1499-1507
43. Ravani P., Tripepi G., Malberti F., Testa S., Mallamaci F., and Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease. A competing risks modeling approach. J Am Soc Nephrol 16 (2005) 2449-2455
44. Fliser D., Kronenberg F., Kielstein J.T., et al. Asymmetric dimethylarginine and progression of chronic kidney disease. The mild to moderate kidney disease study. J Am Soc Nephrol 16 (2005) 2456-2461
45. Bennett C.L., Luminari S., Nissenson A.R., et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 351 (2004) 1403-1408
46. Boven K., Stryker S., Knight J., et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 67 (2005) 2346-2353
47. Sharma B., Bader F., Templemen T., et al. Technical investigations into the cause of the increased incidence of antibody-mediated pure red cell aplasia associated with EPREX. Eur J Hosp Pharm 5 (2004) 86-91